Stevens-Johnson syndrome after lenalidomide therapy for multiple myeloma: a case report and a review of treatment options.

Abstract

Stevens- Johnson syndrome (SJS) is a severe and life-threatening condition. Although allopurinol, an antihyperuricemia drug, is the drug most commonly associated with SJS, more than 100 different causative drugs have been reported. Among hematologic drugs recently introduced into the market, drugs such as rituximab, imatinib, and bortezomib are reported. Here, we describe a patient with SJS while receiving lenalidomide in combination with prednisolone for treatment-naïve multiple myeloma. Although SJS has been reported rarely as an adverse reaction to Lenalidomide, this drug should be considered in the etiology of SJS, and the increased number of prescriptions of Lenalidomide for the therapy of multiple myeloma has to stress the awareness of its potentially serious side-effects.

• Authors: Alessandro Allegra, Andrea Alonci, Giuseppa Penna, Sabina Russo, Demetrio Gerace, Bruna Greve, Arianna D'Angelo, Sara Catena, Caterina Musolino
• Journal: Hematological oncology (Hematol Oncol) Vol. 30 Issue 1 Pg. 41-5 (Mar 2012) ISSN: 1099-1069 [Electronic] England
• PMID: 21702057 (Publication Type: Case Reports, Journal Article, Review)
• Copyright: Copyright © 2011 John Wiley & Sons, Ltd.

Chemical References

• Thalidomide
• Prednisolone
• Lenalidomide

Topics

• Aged
• Antineoplastic Combined Chemotherapy Protocols (adverse effects, therapeutic use)
• Female
• Humans
• Lenalidomide
• Multiple Myeloma (drug therapy)
• Prednisolone (administration & dosage)
• Stevens-Johnson Syndrome (chemically induced)
• Thalidomide (administration & dosage, adverse effects, analogs & derivatives)